Oppenheimer analyst Jay Olson maintained a Buy rating on TherapeuticsMD (TXMD) yesterday and set a price target of $14. The company’s shares closed yesterday at $5.10.
“We met management for an update on Imvexxy launch progress and plans for the Bijuva and Annovera launches. The Imvexxy launch continues to set the standard for best-in-class with an initial trajectory on track to double the uptake of the most recent competitive launch. With the Bijuva launch on the horizon (likely 2Q, in our view), we note several important synergies with Imvexxy that TXMD plans to leverage. Many women experience hot flashes and VVA, providing TXMD an opportunity to educate and expand both markets. We continue to view Bijuva as a significant opportunity with ~2x the peak sales potential compared to Imvexxy and, therefore, the dominant value driver for TXMD shares while Annovera (2H19 launch) represents an under- appreciated source of additional upside. Details inside.”
According to TipRanks.com, Olson ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -8.3% and a 37.7% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Conatus Pharmaceuticals, and Enanta Pharmaceuticals.
Currently, the analyst consensus on TherapeuticsMD is a Strong Buy with an average price target of $19, which is a 272.5% upside from current levels. In a report issued on January 21, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $27 price target.
See today’s analyst top recommended stocks >>
Based on TherapeuticsMD’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $35.61 million. In comparison, last year the company had a GAAP net loss of $21.43 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.
Read More on TXMD: